Oropharyngeal and proximal esophageal involvement during adalimumab treatment of Crohn disease.
Nguyen
Kim-Doan Katrina
KD
Division of Pediatric Gastroenterology, Hepatology, and Nutrition, SUNY Downstate Medical Center, 445 Lenox Road, Brooklyn, NY 11203, USA. mdkatrina@earthlink.net
Alexis
Richard
R
Schwarz
Steven M
SM
D000068879:Adalimumab; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D003424:Crohn Disease / Q000150:complications* / Q000188:drug therapy; D004935:Esophageal Diseases / Q000209:etiology*; D004947:Esophagus; D005260:Female; D006801:Humans; D009960:Oropharynx; D010608:Pharyngeal Diseases / Q000209:etiology*; D055815:Young Adult
D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068879:Adalimumab